> Contact
> Homepage
> Site map
> Links

About HIFU
About Ablatherm
Clinical Information
Clinical Results
  Large Cohort Studies
  Long Term Results
  Radiotherapy Failures
  Safety Results
Clinical Trials


Published Abstracts
& Articles
Video Clips
 You are here : Physicians > HIFU - Ablatherm > Clinical Results > Long Term Results

Long-term results have been published…

A 5-year experience was reported on 146 consecutive T1-T2 prostate cancer patients, with a PSA level of 15 ng/ml or less. The patients were treated with Ablatherm in the University of Regensburg, Germany, between October 1997 and November 2002.

 

The median PSA nadir achieved after 3 months was 0.07 ng/ml and the median PSA level after a follow-up of 22 months was 0.15 ng/ml. 93.4% of all patients had negative control biopsies. No severe stress incontinence was observed. Erectile function was preserved in 47.3% of patients, and the International Prostate Symptom Score and Quality of Life Index did not change from before to after treatment.

The results demonstrated the efficacy and low-associated morbidity of HIFU. HIFU seems to be a valid alternative treatment for patients who are not eligible for radical prostatectomy or who do not want to experience the potential side effect of the operation.

(1) High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer:
5-year Experience . A. Blana, B. Walter, S. Rogenhofer, W.F. Wieland, University of Regensburg, Dept. Of Urology, Germany. Urology 63 (2), p. 297-300, 200

Last update: July 2004

® Ablatherm is aregistered trademark of EDAP.
© Copyright 2004 EDAP. All rights reserved.